Skye Bioscience's novel CB1 antibody nimacimab demonstrated 23.5% weight loss as monotherapy in diet-induced obesity models, comparable to effects seen with tirzepatide and monlunabant.
This week's clinical trials round-up highlights significant advancements in treatments for various conditions, including idiopathic pulmonary fibrosis, diabetes, COPD, and advanced solid tumours. Key developments include positive Phase 2 results for Faron Pharmaceuticals' BEXMAB trial, AstraZeneca's Phase 2a COURSE trial for COPD, and Johnson & Johnson's Phase 3 QUASAR maintenance study for ulcerative colitis.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.